FDA advisors pushed for nuance in discussing whether andexanet alfa (Andexxa) should gain full approval, citing uncertainties about which dose and in which patients it could be best used to stop ...

Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume but was associated with ...

Intracerebral hemorrhage (ICH) is a serious and often life-threatening condition, particularly in patients taking anticoagulants such as factor Xa inhibitors for prevention of blood clots. The rapid ...

Please provide your email address to receive an email when new articles are posted on . AstraZeneca announced a postmarketing trial assessing safety and efficacy of andexanet alfa stopped early due to ...

On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc’s (NASDAQ:AZN) supplemental biologics license application for Andexxa (coagulation factor Xa ...

The andexanet formulation included 500 mg of mannitol per vial. The use of a high-dose or low-dose bolus was in accordance with the label approved by the Food and Drug Administration and was based on ...

In patients with intracerebral hemorrhage (ICH) who are taking factor Xa inhibitor anticoagulants, andexanet alfa (Andexxa/Ondexxya, AstraZeneca) rapidly reduced antifactor Xa (anti-Xa) activity and ...